O'Malley F P, Vnencak-Jones C L, Dupont W D, Parl F, Manning S, Page D L
Department of Pathology, Vanderbilt University, Nashville, Tennessee.
Lab Invest. 1994 Jul;71(1):67-72.
Mutations in the p53 tumor suppressor gene have been identified in breast and many other carcinomas. It is not clear, however, when these mutations occur during breast carcinogenesis. Overexpression of 53 protein has been reported in some ductal carcinoma in situ (DCIS) lesions. To further study the overexpression of p53 in DCIS of the breast and correlate these findings with changes at the molecular level, we performed p53 immunostaining and direct sequencing in noncomedo and comedo DCIS.
Archival blocks were obtained on cases of noncomedo DCIS, (including encysted, noninvasive papillary carcinoma) and comedo DCIS. Immunohistochemical staining with the p53 antibody DO7 was performed on all cases. Polymerase chain reaction (PCR) amplification of exons 5, 6, and 7 of the p53 gene was performed and the PCR products were directly sequenced. Four comedo DCIS cases that were p53 immunopositive were further screened for p53 mutations by PCR/single strand conformation polymorphism in exons 8 and 9 of the p53 gene. One of these cases showing a mobility shift was directly sequenced.
We examined 39 lesions including comedo DCIS (N = 12) and noncomedo DCIS (N = 27), the latter including 17 encysted noninvasive papillary carcinomas. Immunostaining with DO7 was positive in 4 of 12 comedo DCIS lesions (33%) while all noncomedo lesions including encysted noninvasive papillary carcinomas were negative. Direct sequencing of PCR products confirmed wild-type DNA in exons 5 and 6 in all noninvasive papillary carcinomas, 3 randomly selected noncomedo DCIS lesions, and 4 p53 antibody-positive comedo DCIS lesions. In these latter 4 cases, wild-type DNA sequences were preserved in exon 7 for all cases. A single case had a conformational shift in exon 8 within the four cases screened in exons 8 and 9. Direct DNA sequencing of this exon revealed a G to A point mutation resulting in an arginine-to-histidine substitution at codon 273 of the protein.
Our results suggest that mutant p53 protein accumulation in preinvasive lesions is limited to comedo (high grade) DCIS and that p53 positivity by immunohistochemistry does not correlate in all cases with specific p53 mutations in exons 5 to 9, the most highly conserved regions of this gene.
在乳腺癌及许多其他癌症中已发现p53肿瘤抑制基因突变。然而,尚不清楚这些突变在乳腺癌发生过程中的何时出现。已有报道称在一些导管原位癌(DCIS)病变中存在p53蛋白过表达。为进一步研究p53在乳腺DCIS中的过表达情况,并将这些发现与分子水平的变化相关联,我们对非粉刺型和粉刺型DCIS进行了p53免疫染色及直接测序。
获取非粉刺型DCIS(包括囊性、非浸润性乳头状癌)和粉刺型DCIS病例的存档蜡块。对所有病例进行p53抗体DO7的免疫组织化学染色。对p53基因的第5、6和7外显子进行聚合酶链反应(PCR)扩增,并对PCR产物进行直接测序。对4例p53免疫阳性的粉刺型DCIS病例,通过PCR/单链构象多态性进一步筛查p53基因第8和9外显子中的突变。其中1例出现迁移率改变的病例进行直接测序。
我们检查了39个病变,包括粉刺型DCIS(n = 12)和非粉刺型DCIS(n = 27),后者包括17例囊性非浸润性乳头状癌。DO7免疫染色在12例粉刺型DCIS病变中的4例呈阳性(33%),而所有非粉刺型病变包括囊性非浸润性乳头状癌均为阴性。PCR产物的直接测序证实,所有非浸润性乳头状癌、3例随机选择的非粉刺型DCIS病变以及4例p53抗体阳性的粉刺型DCIS病变的第5和6外显子均为野生型DNA。在这4例后者病例中,所有病例的第7外显子均保留野生型DNA序列。在第8和9外显子筛查的4例病例中,有1例第8外显子出现构象改变。该外显子的直接DNA测序显示一个G到A的点突变,导致蛋白质第273密码子处的精氨酸被组氨酸取代。
我们的结果表明,p53突变蛋白在浸润前病变中的积累仅限于粉刺型(高级别)DCIS,并且免疫组织化学检测到的p53阳性在所有病例中与该基因最保守区域第5至9外显子中的特定p53突变并不相关。